Navigation Links
Prometheus Launches Next Generation IBD Diagnostic Test

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® IBD sgi Diagnostic™ test. The PROMETHEUS IBD sgi Diagnostic is Prometheus' 4th-generation IBD diagnostic test and the first and only test to combine serologic, genetic, and inflammation markers, hence "sgi", in the proprietary Smart Diagnostic Algorithm for added diagnostic clarity.  

This novel diagnostic test represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests and complements the innovative PROMETHEUS® Crohn's Prognostic.  PROMETHEUS IBD sgi Diagnostic aids healthcare providers in differentiating IBD vs non-IBD, and Crohn's disease (CD) vs. ulcerative colitis (UC), in one comprehensive blood test. Evidence suggests IBD is primarily caused by a deregulated mucosal inflammatory response to intestinal bacteria in genetically susceptible individuals.

This new test will replace the currently available PROMETHEUS® IBD Serology 7 (except in New York where it is pending approval by the NY Department of Health).  

"By now combining three important components strongly associated with IBD, serology (antibodies to bacteria), genetics, and inflammation markers, we believe this novel test represents a significant improvement in helping physicians diagnose their patients with suspected IBD," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "This new test demonstrates almost 20% relative improvement in differentiating CD versus UC as compared to our prior test."

About IBD

IBD, including Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the intestinal tract. Symptoms of the disease may include diarrhea, abdominal pain, fever and rectal bleeding. Patients may require long-term medical care, including hospitalizations, surgeries and therapeutics. The condition can be difficult to diagnose and manage clinically while consuming a substantial amount of healthcare resources in terms of physician time, procedures and medications. Approximately 1.4 million Americans suffer from IBD.  

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus has become part of Nestle Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit

About Nestle Health Science

Nestle Health Science, a fully-owned subsidiary of Nestle S.A., is operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit

SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
2. Prometheus Announces Agreement to be Acquired by Nestle Health Science
3. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
4. Prometheus Highlights Record Performance in 2010
5. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
8. Prometheus Launches ProOnc Dx Cancer Diagnostics
9. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
10. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
11. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
Post Your Comments:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology:
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):